CD8A and melanoma: Anti-CTLA-4 mAb and anti-CD40 mAb administered with liposome-encapsulated peptide vaccine or an adenoviral vector encoding melanoma antigen induced effective tumor-specific CD8+ T cells with no detrimental side effects [108,109].